Skip to main content

​New data on use of TIGR® Matrix surgical mesh in Immediate Breast Reconstruction

Press Release   •   Apr 12, 2016 13:28 GMT

New data on use of TIGR® Matrix surgical mesh in Immediate Breast Reconstruction

A new clinical study evaluating the role of TIGR® Matrix in immediate implant-based breast reconstruction has been published ahead of print by the journal Breast Cancer Management.

The study, a single-center, post-procedure investigation, monitored the safety and performance of TIGR® Matrix in adult patients suitable for immediate implant breast reconstruction following skin-sparing mastectomy.

TIGR® Matrix was used in 29 patients undergoing a total of 37 mastectomies and immediate reconstructions. Indications for mastectomy were breast cancer in 29 cases and BRCA 1 or 2 mutations in eight cases.

Early postoperative results showed no adverse reactions to the mesh as well as good tissue integration. The author, Dr Peter Schrenk, Linz, Austria concluded that TIGR® Matrix surgical mesh fulfilled many desired characteristics and requirements for use in implant-based breast reconstruction.

Read more at:

About Novus Scientific

Novus Scientific AB ( develops, manufactures and markets resorbable implants that help the body's own healing. Headquarters, research and production are located in Uppsala, Sweden and sales are made through distributors in a growing number of countries, currently around twenty-five.

TIGR® Matrix surgical mesh is a slowly degradable synthetic surgical mesh that contributes mechanical strength until the body itself recreates tissue strength. It is then excreted through natural pathways. TIGR® Matrix is used today in a variety of surgical application areas to reinforce soft tissue where weakness exists.

For more information about TIGR® Matrix, visit: